I agree that this site is using cookies. You can find further informations here.
X
Lickliter, Jason
111  results:
Search for persons X
?
1

Icanbelimod (CBP-307), a next-generation Sphingosine-1-phos..:

Lickliter, Jason ; Yang, Xin ; Guo, Jiawang..
Frontiers in Immunology.  15 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
2

Pharmacokinetics, pharmacodynamics, and tolerability of an ..:

Modi, Nishit B. ; Shames, Richard ; Lickliter, Jason D..
European Journal of Haematology.  , 2024
Link: https://doi.org/10.1111/..
 
?
3

First-in-human trial evaluating safety and pharmacokinetics..:

Zhou, Xiao-Jian ; Lickliter, Jason ; Montrond, Maureen...
Antimicrobial Agents and Chemotherapy.  68 (2024)  5 - p. , 2024
Link: https://doi.org/10.1128/..
 
?
4

A phase I trial of SON-1010, a tumor-targeted, interleukin-..:

Kenney, Richard T. ; Cini, John K. ; Dexter, Susan...
Frontiers in Immunology.  15 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
5

42273 Phase 1 Study in Healthy Adults of the Safety, Tolera..:

Dillon, Stacey R. ; Davies, Rupert H. ; Lickliter, Jason D....
Journal of the American Academy of Dermatology.  89 (2023)  3 - p. AB74 , 2023
Link: https://doi.org/10.1016/..
 
?
6

Dodecafluoropentane Emulsion as a Radiosensitizer in Gliobl..:

Lickliter, Jason D. ; Ruben, Jeremy ; Kichenadasse, Ganessan...
Cancer Research Communications.  3 (2023)  8 - p. 1607-1614 , 2023
Link: https://doi.org/10.1158/..
 
?
7

#4024 PHASE 1 STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKI..:

Dilllon, Stacey ; Davies, Rupert ; Lickliter, Jason...
Nephrology Dialysis Transplantation.  38 (2023)  Supplement_1 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
8

A phase I randomized, double‐blinded, placebo‐controlled st..:

Lickliter, Jason ; Wang, Shuang ; Zhang, Wenxin...
Clinical and Translational Science.  16 (2023)  9 - p. 1691-1703 , 2023
Link: https://doi.org/10.1111/..
 
?
9

Strong CD4+ T-Cell Responses to Ancestral and Variant Spike..:

Fries, Louis ; Formica, Neil ; Mallory, Raburn M...
The Journal of Infectious Diseases.  228 (2023)  6 - p. 734-741 , 2023
Link: https://doi.org/10.1093/..
 
?
10

S276: POVETACICEPT (ALPN-303), A POTENT DUAL BAFF/APRIL ANT..:

Dillon, Stacey ; Davies, Rupert ; Lickliter, Jason...
HemaSphere.  7 (2023)  S3 - p. e3301055 , 2023
Link: https://doi.org/10.1097/..
 
?
11

Topical application of a novel anti‐interleukin‐17A antibod..:

Sinclair, Rodney ; Sharifeh, Sammy ; Thackwray, Susan...
Experimental Dermatology.  32 (2023)  9 - p. 1538-1545 , 2023
Link: https://doi.org/10.1111/..
 
?
12

Paltusotine, a novel oral once-daily nonpeptide SST2 recept..:

Madan, Ajay ; Markison, Stacy ; Betz, Stephen F....
Pituitary.  25 (2022)  2 - p. 328-339 , 2022
Link: https://doi.org/10.1007/..
 
?
13

A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3..:

Gan, Hui K. ; Millward, Michael ; Jalving, Mathilde...
The Oncologist.  26 (2021)  10 - p. e1844-e1853 , 2021
Link: https://doi.org/10.1002/..
 
?
14

A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel ..:

Chen, Michael C. ; Korth, Christopher C. ; Harnett, Mark D...
Clinical Pharmacology in Drug Development.  11 (2021)  2 - p. 220-234 , 2021
Link: https://doi.org/10.1002/..
 
?
15

Cellular responses at the application site of a high-densit..:

Depelsenaire, Alexandra C. I. ; Witham, Katey ; Veitch, Margaret...
PLOS ONE.  16 (2021)  7 - p. e0255282 , 2021
Link: https://doi.org/10.1371/..
 
1-15